Hospital Cuf Descobertas S.A.
- Address
- lock Available on a paid plan
Oncology Clinical Research
Hospital Cuf Descobertas S.A. leads a robust oncology program investigating advanced breast cancer, non‑small cell lung cancer, and other solid tumours. The trials focus on testing new targeted agents, immunotherapies, and combination regimens to improve survival and disease control.
- Targeted therapies for HER2‑low and hormone‑receptor positive breast cancer
- KRAS G12C inhibitors in NSCLC
- Novel immunotherapy combinations for head and neck squamous cell carcinoma
With over 30 investigators, the oncology portfolio contributes to personalized cancer treatment advances across Europe.
Dermatology and Skin Disease Studies
The site conducts multiple trials addressing atopic dermatitis, hidradenitis suppurativa, and other inflammatory skin conditions. Research aims to evaluate innovative biologics and small molecules to reduce symptoms and improve quality of life.
- Biologic therapies for moderate‑to‑severe atopic dermatitis
- Novel agents for hidradenitis suppurativa treatment
- Interventions targeting pruritus in chronic skin diseases
These studies involve multidisciplinary collaboration to bring new dermatologic options to patients.
Respiratory and Pulmonary Research
Clinical investigations at Hospital Cuf Descobertas S.A. target asthma, chronic obstructive pulmonary disease, and lung cancer subtypes. The purpose is to assess new inhaled therapies and systemic agents that enhance lung function and reduce exacerbations.
- Inhaled corticosteroid/bronchodilator combinations for uncontrolled asthma
- Therapies for COPD symptom management
- Targeted treatments for EGFR‑mutated lung cancer
These efforts support improved respiratory health for both adult and pediatric populations.
Cardiovascular and Metabolic Trials
The hospital’s cardiovascular research focuses on hypertrophic cardiomyopathy and metabolic disorders such as obesity. Trials are designed to evaluate novel cardiac myosin inhibitors and weight‑loss agents for safety and efficacy.
- Myosin inhibition for symptomatic hypertrophic cardiomyopathy
- Weight‑reduction therapy combined with lifestyle counseling
- Metabolic pathway modulators for obesity management
These studies aim to provide new therapeutic options for patients with heart muscle disease and metabolic challenges.
Autoimmune and Rare Disease Investigations
Research at the site includes trials for systemic lupus erythematosus, primary Sjögren’s syndrome, and neurodegenerative conditions like frontotemporal dementia. The objective is to test innovative immunomodulators and disease‑modifying agents.
- Targeted biologics for cutaneous lupus erythematosus
- Immunotherapy for primary Sjögren’s syndrome
- Novel compounds addressing neurodegeneration in frontotemporal dementia
These programs reflect a commitment to advancing care for rare and complex immune‑mediated diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 12 therapeutic areas and 15 of 127 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 127 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1Novartis Pharma AG3active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Cuf Descobertas S.A.
lock Showing 1 of 77 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized Withdrawal Study of Subcutaneous Secukinumab for Long-Term Efficacy and Safety in Moderate to Severe Hidradenitis Suppurativa | Novartis Pharma AG | Phase III | Not Recruiting | Mar 2020 | Jun 2026 |
IMP list
lock Showing 1 of 127 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2018-12-13 | 2026-01-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.